参考文献/References:
[1].Carbone S,Canada JM,Billingsley HE,et al. Obesity paradox in cardiovascular disease:where do we stand[J]. Vasc Health Risk Manag,2019,15:89-100.
[2].Horwich TB,Fonarow GC,Hamilton MA,et al. The relationship between obesity and mortality in patients with heart failure[J]. J Am Coll Cardiol,2001,38(3):789-795.
[3].Antonopoulos AS,Tousoulis D. The molecular mechanisms of obesity paradox[J]. Cardiovasc Res,2017,113(9):1074-1086.
[4].Lechi A. The obesity paradox:is it really a paradox? Hypertension[J]. Eat Weight Disord,2017,22(1):43-48.
[5].Proietti M,Guiducci E,Cheli P,et al. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials[J]. Stroke,2017,48(4):857-866.
[6].McLean LL,Pellino K,Brewis M,et al. The obesity paradox in pulmonary arterial hypertension:the Scottish perspective[J]. ERJ Open Res,2019,5(4):00241-2019.
[7].Dietz MF,Prihadi EA,van der Bijl P,et al. The obesity paradox in patients with significant tricuspid regurgitation:effects of obesity on right ventricular remodeling and long-term prognosis[J]. J Am Soc Echocardiogr,2021,34(1):20-29.
[8].Schwann TA,Ramia PS,Engoren MC,et al. Evidence and temporality of the obesity paradox in coronary bypass surgery:an analysis of cause-specific mortality[J]. Eur J Cardiothorac Surg,2018,54(5):896-903.
[9].Horwich TB,Fonarow GC,Clark AL. Obesity and the obesity paradox in heart failure[J]. Prog Cardiovasc Dis,2018,61(2):151-156.
[10].Mehra MR,Uber PA,Park MH,et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure[J]. J Am Coll Cardiol,2004,43(9):1590-1595.
[11].Mohamed-Ali V,Goodrick S,Bulmer K,et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo[J]. Am J Physiol,1999,277(6):E971-E975.
[12].Weber MA,Neutel JM,Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients[J]. J Am Coll Cardiol,2001,37(1):169-174.
[13].黄磊,丛欣,幺天保,等. 心原性恶病质的药物治疗进展[J]. 国际心血管病杂志,2020,47(1):23-28.
[14].Okoshi MP,Capalbo RV,Romeiro FG,et al. Cardiac cachexia:perspectives for prevention and treatment[J]. Arq Bras Cardiol2017,108(1):74-80.
[15].Hall JE,do Carmo JM,da Silva AA,et al. Obesity-induced hypertension:interaction of neurohumoral and renal mechanisms[J]. Circ Res,2015,116(6):991-1006.
[16].Lavie CJ,Milani RV,Ventura HO. Obesity and cardiovascular disease:risk factor,paradox and impact of weight loss[J]. J Am Coll Cardiol,2009,53(21):1925-1932.
[17].Mebazaa A,Gheorghiade M,Pi?a IL,et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes[J].Crit Care Med,2008,36(1 suppl):S129-S139.
[18].Fonarow GC,Srikanthan P,Costanzo MR,et al. An obesity paradox in acute heart failure:analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry[J]. Am Heart J,2007,153(1):74-81.
[19].Ballard VL,Edelberg JM. Stem cells and the regeneration of the aging cardiovascular system[J]. Circ Res,2007,100(8):1116-1127.
[20].Mehta A,Meng Q,Li X,et al. Vascular regenerative capacity and the obesity paradox in coronary artery disease[J]. Arterioscler Thromb Vasc Biol,2021,41(6):2097-2108.
[21].Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.
[22].Anker SD,Negassa A,Coats AJ,et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors:an observational study[J]. Lancet,2003,361(9363):1077-1083.
[23].Anker SD,Ponikowski P,Varney S,et al. Wasting as independent risk factor for mortality in chronic heart failure[J]. Lancet,1997,349(9058):1050-1053.
[24].Josiak K,Jankowska EA,Piepoli MF,et al. Skeletal myopathy in patients with chronic heart failure:significance of anabolic-androgenic hormones[J]. J Cachexia Sarcopenia Muscle,2014,5(4):287-296.
[25].Iacobini C,Pugliese G,Blasetti Fantauzzi C,et al. Metabolically healthy versus metabolically unhealthy obesity[J]. Metabolism,2019,92:51-60.
[26].Smith GI,Mittendorfer B,Klein S. Metabolically healthy obesity:facts and fantasies[J]. J Clin Invest,2019,129(10):3978-3989.
[27].Ortega FB,Lee DC,Katzmarzyk PT,et al. The intriguing metabolically healthy but obese phenotype:cardiovascular prognosis and role of fitness[J]. Eur Heart J,2013,34(5):389-397.
[28].Tobias DK. Addressing reverse causation bias in the obesity paradox is not "one size fits all"[J]. Diabetes Care,2017,40(8):1000-1001.
[29].Kalantar-Zadeh K,Rhee CM,Amin AN. To legitimize the contentious obesity paradox[J]. Mayo Clin Proc,2014,89(8):1033-1035.
[30].Stokes A,Preston SH. Smoking and reverse causation create an obesity paradox in cardiovascular disease[J]. Obesity(Silver Spring),2015,23(12):2485-2490.
[31].Nguyen US,Niu J,Choi HK,et al. Commentary:effect of obesity on mortality:comment on article by Banack and Kaufman[J]. Epidemiology,2014,25(1):2-3.
[32].Virani SS,Alonso A,Benjamin EJ,et al. Heart Disease and Stroke Statistics—2020 Update:a report from the American Heart Association[J]. Circulation,2020,141(9):e139-e596.
[33].Butler J,Howser R,Portner PM,et al. Body mass index and outcomes after left ventricular assist device placement[J]. Ann Thorac Surg,2005,79(1):66-73.
[34].McTigue KM,Hess R,Ziouras J. Obesity in older adults:a systematic review of the evidence for diagnosis and treatment[J]. Obesity(Silver Spring),2006,14(9):1485-1497.
[35].Oreopoulos A,Kalantar-Zadeh K,Sharma AM,et al. The obesity paradox in the elderly:potential mechanisms and clinical implications[J]. Clin Geriatr Med,2009,25(4):643-659,viii.
[36].Antonopoulos AS,Tousoulis D. The molecular mechanisms of obesity paradox[J]. Cardiovasc Res,2017,113(9):1074-1086.
[37].Baker JF,Newman AB,Kanaya A,et al. The adiponectin paradox in the elderly:associations with body composition,physical functioning,and mortality[J]. J Gerontol A Biol Sci Med Sci,2019,74(2):247-253.
[38].Neeland IJ,Gupta S,Ayers CR,et al. Relation of regional fat distribution to left ventricular structure and function[J]. Circ Cardiovasc Imaging,2013,6(5):800-807.
[39].Coutinho T,Goel K,Corrêa de Sá D,et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease:role of "normal weight central obesity"[J]. J Am Coll Cardiol,2013,61(5):553-560.
[40].Kalantar-Zadeh K,Streja E,Kovesdy CP,et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis[J]. Mayo Clin Proc,2010,85(11):991-1001.
[41].Dziura J,Mendes de Leon C,Kasl S,et al. Can physical activity attenuate aging-related weight loss in older people? The Yale Health and Aging Study,1982—1994[J]. Am J Epidemiol,2004,159(8):759-767.
[42].McAuley PA,Artero EG,Sui X,et al. The obesity paradox,cardiorespiratory fitness,and coronary heart disease[J]. Mayo Clin Proc,2012,87(5):443-451.
[43].de Schutter A,Lavie CJ,Milani RV. The impact of obesity on risk factors and prevalence and prognosis of coronary heart disease—the obesity paradox[J]. Prog Cardiovasc Dis,2014,56(4):401-408.
[44].Xia TL,Li YM,Huang FY,et al. The triglyceride paradox in the mortality of coronary artery disease[J]. Lipids Health Dis,2019,18(1):21.
[45].Ruttmann E,Abfalterer H,Dietl M,et al. Positive family history of cardiovascular disease and long-term outcomes after coronary artery bypass grafting:a genetic paradox?[J]. Eur J Cardiothorac Surg,2020,57(5):986-993.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]